Companion Diagnostics and Personalized Medicine Market Report 2012 This is the latest and most up-to-date Market Report fr...
table Of Contentchapter I. personalized Medicine And Companion Diagnostics: Market Segmentation And QuantitativeAnalysisde...
timeline Of Rx/cdx Co-development Over The Last Two Decadesdisparities Between Rx And Cdx Companiesvarying Economic Incent...
Albany NY - 12207United StatesTel: +1-518-618-1030USA - Canada Toll Free 866-997-4948Email: sales@researchmoz.usBlog: http...
Upcoming SlideShare
Loading in …5
×

Companion Diagnostics and Personalized Medicine Market

442
-1

Published on

This is the latest and most up-to-date Market Report from Select Biosciences addressing the companion diagnostics (CDx) and personalized medicine marketplace.Personalized medicine is a broad field with several stakeholders all of which must be aligned in order to capture the immense potential value in targeting therapeutics to the correct patient population—the field of stratified medicine.

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
442
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Companion Diagnostics and Personalized Medicine Market

  1. 1. Companion Diagnostics and Personalized Medicine Market Report 2012 This is the latest and most up-to-date Market Report from Select Biosciences addressing the companiondiagnostics (CDx) and personalized medicine marketplace.Personalized medicine is a broad field with severalstakeholders all of which must be aligned in order to capture the immense potential value in targetingtherapeutics to the correct patient population—the field of stratified medicine. Companion Diagnostics has been rapidly expanding over the past 3 years and in this market report wedescribe the current state of the marketplace from the following perspectives: All the Prognostic and Predictive Biomarkers with Potential Clinical Utility are described—a fewhave already been developed into CDx and we expect growth in this space Targeted Therapeutics, AssociatedBiomarkers, Therapeutic Indications, and Testing Mandates are Described Companion DiagnosticsPartnerships and Collaborations from 2009 to 2012 are Presented—Provides an Up-to-Date State of theIndustry Describing the Disease Areas being Addressed and Types of Biomarkers Being DeployedQuantitative Market Metrics Quantitative Market Forecast: Market Sizing and Growth Rate RevenueBreakout: Rx versus Dx Targeted Rx and CDx Pricing Publication Hotspot Analyses of the Various CancerBiomarker Classes for Identifying Niches of Market Opportunity in Various Disease Classes Thisdata-driven characterization of the Companion Diagnostics and Personalized Medicine field is a hands-ondocument that can be used for competitive benchmarking, business planning, and strategydevelopment—all the data that have been collected in this industry analysis are presented and they formthe basis for the conclusions drawn throughout the market report presented in a format enabling“drag-and-drop” into business presentations/business plans—this Market Report iswritten and delivered to customers in PowerPoint format. Extensive Market Analyses Presented in this Report Personalized Medicine and Companion Diagnostics: Market Segmentation and Quantitative Analysis Prognostic Biomarkers in Cancer Listing, Description, and Clinical Significance Predictive Biomarkers inCancer Listing, Description, and Clinical Significance Summary of Pathways to Regulatory Approval ofCompanion Diagnostics LDTs under CLIA Certification Outcomes with Drugs in Various Disease ClassesPercent of Tumor Classes where Tumors are Associated with Characterized Somatic Mutations CompanionDiagnostics and Personalized Medicine: Quantitative Market Metrics How Much Does it Cost to Develop aCompanion Diagnostic? Precedent for Premium Pricing in Cancer Targeted Therapeutics Pricing of SelectedPersonalized Medicine Tests Growth of the Personalized Medicine Marketplace: Market Size/Forecast andGrowth Rate Personalized Medicine Industry Landscape: Selected Indications, Biomarkers and Therapeutics Market Trends and Evolution of the CDx Marketplace Disparities between Rx and CDx Companies Varying Economic Incentives between Rx and DxDevelopment Increasing Targeted Rx in the Oncology Space and Effect on CDx Development CurrentRx/CDx Co-development Programs in Phase III Trials with Listing of Associated Biomarkers Cancer ClassesAddressable by CDx Characterization of Molecular Biomarker Classes: Hotspot Analysis of PublicationsCancer Biomarkers Oncogenes Tumor Suppressor Genes Non-coding RNAs Collaborations and Partneringin the CDx Space 2012 2011 2010 2009Companion Diagnostics and Personalized Medicine Market Report 2012
  2. 2. table Of Contentchapter I. personalized Medicine And Companion Diagnostics: Market Segmentation And QuantitativeAnalysisdefinition Of Companion Diagnosticsclasses Of Biomarkers And Their Utility In Personalized Medicineprognostic Biomarkers In Cancer Listing, Description, And Clinical Significancepredictive Biomarkers In Cancer Listing, Description, And Clinical Significancechallenges For The Broader Personalized Medicine Field And Its Adoptionsummary Of Pathways To Regulatory Approval Of Companion Diagnosticsldts Under Clia Certificationoutcomes With Drugs In Various Disease Classespercent Of Tumor Classes Where Tumors Are Associated With Characterized Somatic Mutationssomatic Mutation Sequelae In Lung Cancer And Gastrointestinal Cancersxalkori® Storyzelboraf® Storycompanion Diagnostics And Personalized Medicine: Quantitative Market Metricshow Much Does It Cost To Develop A Companion Diagnostic?precedent For Premium Pricing In Cancer Targeted Therapeuticspricing Of Selected Personalized Medicine Testsgrowth Of The Personalized Medicine Marketplace: Market Size/forecast And Growth Ratechapter Ii. personalized Medicine Industry Landscape: Selected Indications, Biomarkers And Therapeuticstherapeuticbiomarkerindicationtesting Mandatethis Comprehensive Listing Frames The Various Personalized Medicine Tests That Are Either“required”, “recommended”, “for Information Use Only”, Or“with No Pharmacogenomic Information On The Drug Label”chapter Iii. market Trends And Evolution Of The Cdx MarketplaceCompanion Diagnostics and Personalized Medicine Market Report 2012
  3. 3. timeline Of Rx/cdx Co-development Over The Last Two Decadesdisparities Between Rx And Cdx Companiesvarying Economic Incentives Between Rx And Dx Developmentincreasing Targeted Rx In The Oncology Space And Effect On Cdx Developmentcurrent Rx/cdx Co-development Programs In Phase Iii Trials With Listing Of Associated Biomarkerscancer Classes Addressable By Cdxcharacterization Of Molecular Biomarker Classes: Hotspot Analysis Of Publicationscancer Biomarkersoncogenestumor Suppressor Genesnon-coding Rnascollaborations And Partnering In The Cdx Space2012201120102009appendix I.research Methodologyappendix Ii.listing And Description Of Cancer BiomarkersAbout Us:Transparency Market Research is a market intelligence company providing global business informationreports and services. Our exclusive blend of quantitative forecasting and trends analysis providesforward-looking insight for thousands of decision makers. We are privileged with highly experienced team ofAnalysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques togather, and analyze information. Our business offerings represent the latest and the most reliable informationindispensable for businesses to sustain a competitive edge.Contact:ResearchMoz90 State Street,Suite 700,Companion Diagnostics and Personalized Medicine Market Report 2012
  4. 4. Albany NY - 12207United StatesTel: +1-518-618-1030USA - Canada Toll Free 866-997-4948Email: sales@researchmoz.usBlog: http://researchmoz.blogspot.com/Website: http://www.researchmoz.us/Companion Diagnostics and Personalized Medicine Market Report 2012

×